What's Happening?
Scholar Rock, a biopharmaceutical company, has resubmitted its Biologics License Application (BLA) for apitegromab to the U.S. Food and Drug Administration (FDA). Apitegromab is a muscle-targeted therapy aimed at treating spinal muscular atrophy (SMA)
in children and adults. This resubmission follows a Complete Response Letter from the FDA in September 2025, which was related to observations during a site inspection of Catalent Indiana, LLC, a facility involved in the drug's production. Scholar Rock has since worked with the FDA and Catalent Indiana to address these issues. The resubmission includes a second U.S.-based fill-finish facility to ensure a robust supply chain. Scholar Rock anticipates FDA acceptance of the BLA within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026.
Why It's Important?
The resubmission of the BLA for apitegromab is significant as it represents a potential advancement in the treatment of SMA, a rare and debilitating neuromuscular disease. If approved, apitegromab would be the first muscle-targeted therapy to show significant improvements in motor function for SMA patients. This development could provide a new therapeutic option for individuals with SMA, potentially improving their quality of life. The FDA's engagement and the inclusion of a second fill-finish facility highlight the importance of ensuring a reliable supply chain for the drug, which is crucial for meeting anticipated demand. The approval and subsequent launch of apitegromab could also have economic implications for Scholar Rock and its partners, as well as for the broader biopharmaceutical industry.
What's Next?
Scholar Rock expects the FDA to accept the BLA resubmission within 30 days, followed by a review period of up to six months. The company is preparing for potential approvals and launches of apitegromab in both the U.S. and Europe later this year. The European Medicines Agency is also reviewing the Marketing Authorisation Application for apitegromab, with a decision anticipated mid-2026. Scholar Rock will continue to engage with regulatory agencies to ensure compliance and address any further requirements. The company is also hosting a conference call to discuss the resubmission and its implications.
